Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411


Share on StockTwits

Investor Ideas Potcasts #583, Cannabis News and Stocks on the Move; (OTC: ROSN), (TSXV: NUMI), (TSXV: HITI) (NASDAQ: HITI) (CSE: HBOR)

 

Delta, Kelowna, BC - July 6, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/070621-StocksToWatch.mp3

Investor Ideas Potcasts #583, Cannabis News and Stocks on the Move; (OTC:ROSN), (TSXV: NUMI), (TSXV: HITI) (NASDAQ: HITI) (CSE: HBOR)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few public and private company announcements.

Harborside Inc. (CSE: HBOR), (OTCQX: HBORF) a California-focused, vertically integrated cannabis enterprise, announced the completion of its previously announced acquisition of Sublimation Inc. ("Sublime"), an award-winning cannabis manufacturing company located in Oakland, CA, for a total consideration of US$43.8 million.

"We are thrilled to complete this Acquisition and add Sublime's talent and its iconic, award-winning California brand, with an exceptional product offering and consumer following, to our growing brand portfolio," said Peter Bilodeau, Interim CEO of Harborside. "With a strong balance sheet and deep cultivation and brand building expertise, our unified company is well-positioned to support the continued growth of the Sublime brands while expanding the reach of Harborside's existing branded product portfolio in both the retail and wholesale markets."

Ahmer Iqbal, CEO of Sublime, added, "We are thrilled to officially join forces with Harborside

and create a leading California house of brands. Together, we can leverage our vast production and retail capabilities to further expand the distribution of our suite of branded products. On behalf of my team, we look forward to commencing the integration process and working together to scale Harborside's reach."

Founded in 2016, Sublime is best known for its expansive line of high-potency, high-quality and affordable, Fuzzies branded pre-rolls, a leading brand of pre-rolls in the state of California, as well as vapes and roll-your-own flower kits. Since 2019, Sublime has delivered a revenue CAGR of approximately 70%, and ended 2020 with 7.9% California pre-roll market share.(4) Sublime is strategically positioned for continued growth as pre-rolls are the fastest growing cannabis sub-segment within the California market since the beginning of 2020.(4)

Harborside expects to realize significant synergies by bringing together Sublime's brands, production capabilities and robust distribution system with the high-quality cannabis grown at the Company's Salinas, California cultivation facility which is anticipated to result in additional gross profit and EBITDA by extending the reach of Sublime, Harborside and Key branded products throughout the state of California.(1)(2)(3) Harborside also expects to bolster Sublime's marketing capabilities, which is expected to drive higher retail margins for the Company as an owned brand within its portfolio.(2)(3) Finally, Harborside will seek to license the Fuzzies California lifestyle brand in additional legal recreational markets across the country, particularly those that do not currently have high potency infused products.

High Tide Inc. (TSXV: HITI) (NASDAQ: HITI), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, announced that it has completed the acquisition of DHC Supply LLC operating as Daily High Club.

The Acquisition was completed pursuant to the terms of the merger agreement previously announced by the Company on June 25, 2021, pursuant to which High Tide USA Inc., a Nevada corporation and a wholly-owned U.S. subsidiary of the Company ("Subco"), has acquired 100% of the issued and outstanding shares of Daily High Club.

Pursuant to the terms of the acquisition, the total consideration to Daily High Club shareholders for all the issued and outstanding securities of Daily High Club is: (i) 839,820 common shares of High Tide valued at US$6.75 Million on the basis of a deemed price per High Tide Share of CAD$9.92, being equal to the volume weighted average price per High Tide Share on the TSX Venture Exchange for the 10 consecutive trading days preceding the closing of the Transaction; and (ii) US$3.25 million in cash.

In connection with the Closing, Harrison Baum, Chief Executive Officer of Daily High Club, has joined the High Tide team as Director of Digital Marketing to oversee all social media initiatives for High Tide globally.

The High Tide Shares issued pursuant to the Share Consideration are subject to a statutory hold period of four months and one day. In addition, the High Tide Shares having a value of 25% of the Consideration will be held in escrow to insure certain indemnification obligations if claims arise.

Furthermore, High Tide granted 13,333 stock options to Harrison Baum, exercisable at CAD$9.39 per High Tide Share for a period of three years.

Numinus Wellness Inc. (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced that the Company has agreed to acquire the Neurology Centre of Toronto ("NCT") pursuant to a purchase agreement dated July 2, 2021. Numinus and NCT founder Dr. Evan Lewis plan to expand NCT into a comprehensive clinical neurology treatment centre with a unique specialization in the application of psychedelics in the field of neurology.

Numinus will pay $300,000 in cash and $200,000 in Numinus shares upon closing and future performance-based payments totaling up to $500,000 in Numinus shares to complete the transaction. The transaction is subject to a number of conditions, including the approval of the TSX Venture Exchange. As of the date hereof, Numinus and NCT management have completed their due diligence. The Company anticipates that the acquisition of NCT will be completed by the end of August 2021.

Transaction Highlights:

  • Numinus to acquire a fully operational neurology centre with 13 doctors, 8 allied health staff, nurse practitioners and physician assistants. Gross revenues for the centre grew more than 25% to approximately $1 million for the year ended December 31, 2020, while net revenue grew 25% to $454,000 for the same period.
  • NCT offers experience managing patients with common neurological conditions and associated chronic psychological disorders for whom there is potential to benefit from psychedelic-assisted psychotherapy.
  • NCT's expertise in clinical neurology and associated mental health disorders will be integrated with Numinus' leadership in psychedelic-assisted psychotherapy to establish the field of psychedelic neurology, to develop strategies and treatments for those with select neurological and concurrent disorders.
  • NCT and Numinus plan to establish the first centre for excellence in psychedelic neurology, comprising highly specialized neurology experts with an understanding of how psychedelics can safely and positively impact patients with neurologic illnesses and associated mental health challenges.
  • Numinus to leverage and grow NCT's information technology-based virtual rapid access care model to streamline and scale pathways for patients to access psychedelic-assisted psychotherapies.
  • Lewis, recognized for advancing the use of medical cannabis to treat complex neurologic disorders, will join Numinus as VP, Psychedelic Neurology Services upon completion of the acquisition.

"Our collaboration with Numinus represents an important evolution in patient care for individuals suffering from common neurological illnesses and challenges that are often associated with chronic mental health conditions," said Dr. Lewis, a neurologist and clinical neurophysiologist who founded NCT in 2017. "While today's treatments help many patients, a significant number continue to suffer and, we believe, may be helped by psychedelic-assisted psychotherapy."

Currently, therapies for common neurological disorders such as concussion, migraine and cluster headache, neuropathic pain syndromes and chronic epilepsy have limitations, especially when these disorders are associated with chronic psychological challenges. The need to develop novel therapies that address both medical and psychological components of neurological diseases may be substantial and the potential impact could be significant.

Numinus and NCT are coming together to explore and develop applications of psychedelic-assisted therapies to reduce patient suffering and enable greater opportunities for healing. Current research shows that psychedelic medications such as psilocybin and MDMA open new pathways in the brain that, in conjunction with professional therapy, can treat a host of mental health disorders.

"This acquisition represents an exciting opportunity for NCT and Numinus to combine medical, clinical and academic expertise to help create a new discipline and ultimately a centre for excellence in psychedelic neurology," said Dr. Evan Wood, Chief Medical Officer, Numinus. "In doing so, this collaborative discipline could potentially make a transformative difference for many patients."

In addition, NCT has developed a virtual rapid access model for patient intake and evaluation that is efficient, team-based and readily modifiable to support specialized programs across various disciplines. The rapid access model is cost-effective, supports and streamlines patient care, reduces wait lists, addresses some barriers to care, and has scale potential. NCT and Numinus will explore how this innovative model can support the development and delivery of efficient, patient-centered psychedelic-assisted psychotherapy.

"I continue to be humbled by the quality of people joining Numinus and acting with us on our ambition to help people heal and be well," said Payton Nyquvest, Numinus CEO and Chair.

"The acquisition of NCT reflects our thoughtful expansion strategy to add clinics that offer revenue-generating services, accretive assets and innovative leadership that maintains our position at the forefront of client care and psychedelic-assisted therapy."

All of NCT's staff - including medical doctors, nurses, physician assistants, occupational therapists, psychotherapists, physiotherapists, nutritionists and administrative staff - are expected to remain with Numinus post transaction closing.

ROSINBOMB (OTC:ROSN) and ARDENT industry leading developers and manufacturers of highly acclaimed groundbreaking solventless extraction and infusion technology products announced today the launch of two exclusive limited edition solution bundles in time for 710. The Press n' Fuse™ bundles are designed to provide the consumer, prosumer and processor an end to end elegant and simple solution for crafting high quality solventless extracts and infused consumables in various formats.

The Rosinbomb™ Rocket is widely acclaimed as the best personal, solventless rosin press in the world, together with the heralded Ardent Nova™ bundle ensures the consumer is well equipped to craft high quality products like the experts. The Press n' Fuse™ product bundle is made for consumers to easily and cost effectively craft, create and enjoy.

The Rosinbomb M-60 with Flow Channel Technology™ the world's first and only volume processing extraction press is teamed up with revolutionary Ardent FX Decarboxylator to create The Press n' Fuse Pro™ and is targeted towards the prosumer/ processor market proving the user with limitless options for crafting any and all forms and quantities of extracts and infused products.

Rosinbomb's CEO, Fred Angelopoulos said, "We are super excited to team up with Ardent to provide this end-to-end solution to the market for 710. I believe our two companies share the same product culture, one which represents best of breed design and performance, innovation, industry leading quality all within a clean and organic environment."

"We believe strongly in empowering and enabling the consumer to take pride and ownership of what they are crafting and consuming and these Press n' Fuse™ bundles are a big step in that direction" added Rosinbomb Founder and President Ryan Mayer.

Ardent founder and CEO Shanel Lindsay discussed the roots of the Company when describing the collaboration, "Ardent was founded on the principles of education and empowering people to take charge of their own wellness and do it in a safe and holistic way. We believe Rosinbomb shares that philosophy, and this collaboration embodies that"

The collaborations are available at https://www.rosinbomb.com/pages/rosinbombardentbundle. The pricing for the two kits is $749 for the Press n' Fuse (list price individually $899) and $1449 for the Press n Fuse Pro (list price individually $2235) and are available for a limited time while supplies last.

710 represents the date of July 10th which is considered to be the industry celebration for the oils and extracts marketplace.

ROSINBOMB continues to be celebrated by experts and leading media outlets. Forbes.com called the Rocket 'Revolutionary Technology That Creates Perfect THC/CBD Rosin Every time' and Tech expert website Engadget named the Rocket 'The Panini Press Of Weed.'

To view the complete line of Rosinbomb presses and accessories please visit http://www.rosinbomb.com.

Lastly today, in an unprecedented move, Health Canada is proposing a full federal ban on vaping flavours. The ban would take effect in about 180 days, so likely January 1, 2022.

"Health Canada is pushing smokers back to smoking cigarettes and into the arms of 'Big Tobacco'," says Shai Bekman, president of DashVapes Inc., Canada's largest independently owned e-cigarette company that produces e-cigarettes, an alternative to smoking.

In a homage to Saturday Night Live's (SNL) "cold open," DashVapes has produced a short skit, titled "The First Vaping-Cessation Device.

"This is not me editorializing or being sarcastic, this is what the report commissioned by Health Canada says. The report freely admits that Canadians are likely to resume smoking cigarettes if vaping flavours are banned," adds Mr. Bekman.

According to a "Regulatory Analysis Impact Statement," pertaining to the Order Amending

Schedules 2 and 3 to the Tobacco and Vaping Products Act (Flavours), published in The Canada Gazette, Ottawa, Saturday, June 19, 2021, states:

"About 46% of current vapers (past-30-day use) aged 20 years and older are dual users (i.e. individuals who vape and smoke cigarettes). The total profit loss to the vaping industry that also manufactures tobacco products may be mitigated by the substitution of tobacco purchases from dual users who would go back to smoking and adults who smoke who would continue to smoke instead of switching to tobacco- or mint/menthol-flavoured vaping products.

After the proposal comes into force, it is anticipated that some dual users who currently use flavoured vaping products would not substitute their purchases with tobacco and mint/menthol-flavoured vaping products. They would choose to purchase more cigarettes, hence offsetting the loss of sales of tobacco- and mint/menthol flavoured vaping products."

Page 140 of the report [emphasis added].

"How would banning vaping flavours help Canadians who are trying to quit smoking?" says Mr. Bekman, a reformed smoker of a 2-packs-per-day habit for 13 years. While he wanted to quit smoking, nothing worked for him until he tried vaping.

"That's like telling recovering alcoholics that they cannot drink iced tea with lemon. Instead, they must drink alcohol-free beer. Does that make sense to anyone?" says Mr. Bekman.

The Health Canada report makes no mention of the fact that there are hundreds of flavour additives in regular cigarettes. According to the American Food and Drug Administration (FDA), There are more than 7,000 chemicals in cigarette smoke. More than 70 of those chemicals are linked to cancer.

"Yes, there is nicotine in e-liquid used to vape, but the whole point of vaping is to reduce your harm," says Mr. Bekman.

"To be clear, DashVapes supports capping nicotine at 20mg per milliliter. DashVapes also supports a ban on advertising to those 19 and younger," he says.

At the same time, Mr. Bekman is pushing for answers to the "Youth Vaping Crisis" in August 2019 to early 2020. "Did Health Canada and the government of Canada conduct a criminal investigation into the Youth Vaping Crisis?" he asks.

In a news release distributed on CNW on June 23, 2021, he asked the Hon. Patty Hajdu, the Federal Minster of Health, Iain Stewart, president of Public Health Agency of Canada (PHAC), as well as all provincial health ministers across Canada, asking about the status of the criminal investigation into Canada's "Youth Vaping Crisis" in late summer 2019 to early 2020.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea's original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com